Quick Answer
Regen BioPharma Inc reported Cash and Equivalents of $69.6 thousand for fiscal year 2025.
Regen BioPharma Inc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $69.6K | +9614.4% |
| 2024 | $716.00 | -99.4% |
| 2023 | $121.0K | +136.4% |
| 2022 | $51.2K | -93.0% |
| 2021 | $727.2K | — |
| 2020 | $0.00 | -100.0% |
| 2019 | $7.9K | -2.0% |
| 2018 | $8.0K | -97.0% |
| 2017 | $270.0K | +987.6% |
| 2016 | $24.8K | -78.6% |
| 2013 | $115.9K | +12459.3% |
| 2012 | $923.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $4.6K | +3291.1% | -93.4% |
| September 30, 2025 | $69.6K | +9614.4% | +51422.2% |
| December 31, 2024 | $135.00 | — | -81.1% |
| September 30, 2024 | $716.00 | — | -99.8% |
| December 31, 2021 | $353.5K | — | -51.4% |
| September 30, 2021 | $727.2K | — | +286.4% |
| June 30, 2021 | $188.2K | — | — |
| March 31, 2021 | $0.00 | — | — |
- Regen BioPharma Inc showed an increase of +9614.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Regen BioPharma Inc’s cash and equivalents has grown by 7435.8% (from $923.00 to $69.6 thousand).
- The most recent figure is from Regen BioPharma Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: